Oshadi D

PreclinicalSmall molecule

OOshadi Drug Administration

Oshadi D is one of 6 small molecule programs targeting Absorption. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AbsorptionCompleted

AbsorptionPreclinical

Completed

Competition

Competitive Landscape

6 competitors in Absorption

#DrugCompanyPhaseTrials

Hezkue

AAspargo Labs, Inc

Phase 2

1 2

Cytovene

EExela Pharma Sciences, LLC.

Preclinical

1 3

Rifampicin

Boehringer Ingelheim

Preclinical

1 4

Procysbi

HHorizon Therapeutics Ireland DAC

Preclinical

1 5

Oshadi D

OOshadi Drug Administration

Preclinical

1 6

Aspirin and Plavix

AAssaf-Harofeh Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 1 Diabetes Mellitus2 trials

Efficacy Safety and Tolerability of Multiple Doses of Oshadi Icp (Oshadi Oral Insulin) in Patients With Type 1 Diabetes Mellitus - Phase II Clinical Study

Completed·OOshadi Drug Administration·Phase 2·NCT01973920·12 enrolled

Safety and Tolerability of Oshadi Icp In Patients With Type 1 Diabetes Mellitus - Phase Ib Clinical Study

Completed·OOshadi Drug Administration·Phase 1/2·NCT01772251·10 enrolled

Safety and Efficacy2 trials

Safety and Efficacy of Single Administration of Oshadi Oral Insulin in Type I Diabetes Patients

Completed·OOshadi Drug Administration·Phase 1·NCT01120912·8 enrolled

Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Cancer Treatment

Completed·OOshadi Drug Administration·Phase 1·NCT01201018·7 enrolled

Acute Myeloid Leukemia1 trial

Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients

Suspended·OOshadi Drug Administration·Phase 2·NCT02462265·15 enrolled

Basal Cell Carcinoma1 trial

Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study

Completed·OOshadi Drug Administration·Phase 2·NCT02007317·30 enrolled

Malignant Mesothelioma1 trial

Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment

Suspended·OOshadi Drug Administration·Phase 1/2·NCT01627795·17 enrolled

2 more indications

Small Cell Lung Cancer1 trial

Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer

Unknown status·OOshadi Drug Administration·Phase 2·NCT02134990·20 enrolled

Absorption1 trial

Evaluation of the Influence of Food Regimen on Oshadi D Absorption

Completed·OOshadi Drug Administration·N/A·NCT01327352·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Oshadi D. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oshadi D compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oshadi D. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oshadi Drug Administration company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: OOshadi Drug Administration

Oshadi D

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 1 Diabetes Mellitus2 trials

Safety and Efficacy2 trials

Acute Myeloid Leukemia1 trial

Basal Cell Carcinoma1 trial

Malignant Mesothelioma1 trial

Small Cell Lung Cancer1 trial

Absorption1 trial

References

Drug Info

Quick Facts

Related News